Indian pharma quarterly results

Lupin profit decline in Q2 FY27 and the cost drivers behind lower margins

Lupin Q2 FY27 Results: Sales Rise 14% but Net Profit Falls 22% as Costs Climb

Why the Lupin profit decline of 22.2% happened despite 14% sales growth: employee, manufacturing and depreciation costs, and what management has not said.

Emcure FY27 guidance analysis after Q2 results with revenue growth above 20%

Emcure Pharma Q2 FY27 Results: Revenue Up 24.3% as International Business Surges and Guidance Rises

Megan Wood7 hours ago010 mins

Why the Emcure FY27 guidance matters: revenue growth above 20%, margin expansion and a net cash target, with the debt and execution risks behind it.